| Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials SM Jakob, E Ruokonen, RM Grounds, T Sarapohja, C Garratt, SJ Pocock, ... Jama 307 (11), 1151-1160, 2012 | 1169 | 2012 |
| Darolutamide in nonmetastatic, castration-resistant prostate cancer K Fizazi, N Shore, TL Tammela, A Ulys, E Vjaters, S Polyakov, M Jievaltas, ... New England Journal of Medicine 380 (13), 1235-1246, 2019 | 985 | 2019 |
| Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure M Packer, W Colucci, L Fisher, BM Massie, JR Teerlink, J Young, ... JACC: Heart Failure 1 (2), 103-111, 2013 | 541 | 2013 |
| Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide K Fizazi, N Shore, TL Tammela, A Ulys, E Vjaters, S Polyakov, M Jievaltas, ... New England Journal of Medicine 383 (11), 1040-1049, 2020 | 368 | 2020 |
| Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation E Ruokonen, I Parviainen, SM Jakob, S Nunes, M Kaukonen, ... Intensive care medicine 35, 282-290, 2009 | 351 | 2009 |
| Dexmedetomidine for Long-Term Sedation Investigators: Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: Two randomized controlled … SM Jakob, E Ruokonen, RM Grounds, T Sarapohja, C Garratt, SJ Pocock, ... Jama 307 (11), 1151-1160, 2012 | 185 | 2012 |
| Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function HI Eriksson, JR Jalonen, LO Heikkinen, M Kivikko, M Laine, KA Leino, ... The Annals of thoracic surgery 87 (2), 448-454, 2009 | 166 | 2009 |
| Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use Z Papp, P Agostoni, J Alvarez, D Bettex, S Bouchez, D Brito, V Černý, ... Journal of cardiovascular pharmacology 76 (1), 4-22, 2020 | 147 | 2020 |
| Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta‐blockers CH Bergh, B Andersson, U Dahlström, K Forfang, M Kivikko, T Sarapohja, ... European journal of heart failure 12 (4), 404-410, 2010 | 141 | 2010 |
| Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care: an economic evaluation H Turunen, SM Jakob, E Ruokonen, KM Kaukonen, T Sarapohja, ... Critical care 19, 1-10, 2015 | 101 | 2015 |
| Oral levosimendan in patients with severe chronic heart failure—the PERSIST study MS Nieminen, JGF Cleland, J Eha, Y Belenkov, M Kivikko, P Põder, ... European journal of heart failure 10 (12), 1246-1254, 2008 | 77 | 2008 |
| Population pharmacokinetics of dexmedetomidine in critically ill patients PA Välitalo, T Ahtola-Sätilä, A Wighton, T Sarapohja, P Pohjanjousi, ... Clinical drug investigation 33, 579-587, 2013 | 68 | 2013 |
| Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate … K Fizazi, ND Shore, T Tammela, A Ulys, E Vjaters, S Polyakov, M Jievaltas, ... Journal of Clinical Oncology 38 (15_suppl), 5514-5514, 2020 | 60 | 2020 |
| A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer HKM Vollan, OM Rueda, SF Chin, C Curtis, G Turashvili, S Shah, ... Molecular oncology 9 (1), 115-127, 2015 | 52 | 2015 |
| Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy G Pölzl, J Altenberger, L Baholli, P Beltrán, A Borbély, J Comin-Colet, ... International journal of cardiology 243, 389-395, 2017 | 49 | 2017 |
| Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial MR Smith, N Shore, TL Tammela, A Ulys, E Vjaters, S Polyakov, ... European Journal of Cancer 154, 138-146, 2021 | 41 | 2021 |
| A prospective, double-blind, pilot, randomized, controlled trial of an “embodied” virtual reality intervention for adults with low back pain C Eccleston, E Fisher, S Liikkanen, T Sarapohja, C Stenfors, ... Pain 163 (9), 1700-1715, 2022 | 34 | 2022 |
| Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure A Mebazaa, A Cohen-Solal, F Kleber, M Nieminen, M Packer, S Pocock, ... Critical Care 8, 1-2, 2004 | 34 | 2004 |
| Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC). K Fizazi, ND Shore, T Tammela, I Kuss, MA Le Berre, AF Mohamed, ... Journal of Clinical Oncology 37 (15_suppl), 5000-5000, 2019 | 29 | 2019 |
| Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial A Al-Chalabi, P Shaw, PN Leigh, L van den Berg, O Hardiman, A Ludolph, ... Journal of Neurology, Neurosurgery & Psychiatry 90 (10), 1165-1170, 2019 | 28 | 2019 |
